Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML

Shelley Herbrich, PhD, Natalia Baran, PhDMD, Gheath Alatrash, Eric Davis, MD, Dongxing Zha, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139434

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD

Blood (2019) 134 (Supplement_1): 4099.

https://doi.org/10.1182/blood-2019-130401

Published: 2019

Journal Articles

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Ran Zhao, BS, Sarah Zarabi, MD, Takenobu Nii, PhD, Ondrej Halgas, PhD, Yulia Jitkova, PhD, Vivian Ruvolo, Lauren Heese, Yuki Nishida, MD PhD, Gautam M. Borthakur, MD, Kensuke Kojima, MD PhD, Martin Stogniew, Wolfgang Oster, MD, Emil Pai, PhD, Eric Davis, MD, Hagop M. Kantarjian, MD, Aaron D Schimmer, MD PhD, Michael Andreeff, MD PhD, Jo Ishizawa, MD PhD

Blood (2019) 134 (Supplement_1): 2562.

https://doi.org/10.1182/blood-2019-127101

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 1533.

https://doi.org/10.1182/blood-2019-129311

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Nathan H. Fowler, MD, Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, F. B. Hagemeister, MD, Sheryl G Forbes, Lore Lagrone, Luis Fayad, MD, Hun Ju Lee, MD, R. Eric Davis, MD, Jason R. Westin, MD, Michael Wang, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD

Blood (2018) 132 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2018-99-119592

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Seemana Bhattacharya, PhD, Sujan Piya, PhD, Qi Zhang, PhD, Natalia Baran, PhD MD, Teresa McQueen, MS, R. Eric Davis, MD, Nicholas Cosford, PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 3934.

https://doi.org/10.1182/blood-2018-99-114817

Published: 2018

Journal Articles

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Shelley Herbrich, MS, Keith Baggerly, PhD, Gheath Alatrash, DO, PhD, R. Eric Davis, MD, Michael Andreeff, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 2768.

https://doi.org/10.1182/blood-2018-99-114818

Published: 2018

Journal Articles

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Jinsheng Weng, MD PhD, Kelsey Moriarty, BD, Yong Pan, Man Chun John MA, PhD, Rohit Mathur, PhD, Zheng Zhang, Hiroki Torikai, MD, Sourindra N Maiti, Fuliang Chu, PhD, Xiaoyun Cheng, Swathi Karri, Deepshika Medapalli, Laurence J N Cooper, MD PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2018) 132 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2018-99-115424

Published: 2018

Journal Articles

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Jason R. Westin, MD, Yasuhiro Oki, MD, Loretta Nastoupil, MD, Luis Fayad, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, F. B. Hagemeister, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, MD, Ken H. Young, MD PhD, Timothy J. McDonnell, MD PhD, Richard J. Ford, MD PhD, R. Eric Davis, MD

Blood (2017) 130 (Supplement 1): 189.

https://doi.org/10.1182/blood.V130.Suppl_1.189.189

Published: 2017

Journal Articles

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Loretta Nastoupil, MD, Jason R. Westin, MD, Nathan H. Fowler, MD, Michelle A. Fanale, MD, Felipe Samaniego, MD, Yasuhiro Oki, MD, Ly Dsouza, PA-C, Chizobam Obi, RN, JingJing Cao, Xiaoyun Cheng, Man Chun John MA, PhD, Wang Zhiqiang, Lei Feng, MS, Shouhao Zhou, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 414.

https://doi.org/10.1182/blood.V130.Suppl_1.414.414

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Blood (2017) 130 (Supplement 1): 3068.

https://doi.org/10.1182/blood.V130.Suppl_1.3068.3068

Published: 2017

Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 3089.

https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089

Published: 2017

NARROW

Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only